
Breakthrough for AL amyloidosis patients
After ongoing advocacy from the Myeloma UK team, the Scottish Medicines Consortium approves the first treatment for AL amyloidosis – a true milestone moment.
Since 1997, our supporters have helped transform the lives of the myeloma community. You’ve been at the heart of every achievement listed here. We can never thank you enough.
After ongoing advocacy from the Myeloma UK team, the Scottish Medicines Consortium approves the first treatment for AL amyloidosis – a true milestone moment.
Our Life Worth Living report lays bare the impact of waiting for diagnosis – as we campaign for a greater focus on patients’ quality of life.
ProMMise becomes the first clinical trial developed through our CARP initiative to recruit patients – who are given earlier access to a new drug, belantamab mafodotin.
With 1 in 4 myeloma patients waiting over ten months to get a diagnosis, we increase awareness among healthcare professionals during Blood Cancer Awareness Month.
We launch the Myeloma Data Collaboration to help connect and compare patient data across NHS trusts – a vital step in the hunt for better treatments.
A huge victory for patient power as NICE approves lenalidomide (Revlimid®) maintenance after an initial rejection. It’s the first life-extending maintenance treatment for myeloma.
With limited investment in studies designed to help identify myeloma sooner, we respond – and launch our own Early Diagnosis Research Programme.
Our advocacy is always based on listening to patients. To make the patient voice even louder we launch the Advocacy Partner Panel making it easier for patients to share experiences and insights.
From the beginning of the pandemic, we’re the hub for patients – discovering how myeloma patients are affected and sharing advice and support.
The myeloma community’s unwavering support during the pandemic blows us away. Close to 300 supporters sign-up to our first ever virtual events and find inventive ways to raise over £91,000.
Another win in our campaigning for new treatments, as NICE approves isatuximab for myeloma patients who have relapsed three times.
We pave the way for better, kinder myeloma treatments by launching the Concept and Access Research Programme (CARP) at the University of Leeds.
50p from every £1 ticket in our weekly lottery goes straight to support our work – and in 2019 we celebrate with our 1,000th winner!
We launch a range of easy-to-read guides about myeloma, designed for people with learning disabilities and anyone who struggles to read written English.
The first immunotherapy drug targeting myeloma cells is made available – and patients play a big role by sharing their experiences.
475 myeloma patients join our study to understand which factors matter most when choosing treatment. The results still inform our advocacy for treatments today.
We launch MUK nine, a new trial using state-of-the-art genetic techniques to try and identify the best treatment options for high-risk patients.
We successfully campaign for a new drug – pomalidomide (Imnovid®) – to be introduced on the NHS for patients whose myeloma has come back three times or more.
We’re at the heart of another pioneering trial, known as MUK eleven. It studies cancer-killing viruses and helps paves the way for new biological treatments.
The average time to diagnose myeloma is longer than almost every other cancer. We launch our Early Diagnosis Programme and Steering Committee to change that.
Carfilzomib (Kyprolis®) becomes the latest drug to be approved after we push for it to be made available. It’s used for patients whose myeloma has returned.
In another victory for advocacy, ixazomib (Ninlaro®) is approved for patients whose myeloma returns twice. As ever, we show the difference it will make to patients.
Our scientists discover that the inherited risk of developing myeloma is related to 17 genetic variants. The more we understand the causes, the more we can improve treatments.
We hold our first London to Paris cycle ride, and 125 riders raise an amazing £446,703. The biggest highlight? The unforgettable sense of community.
We work with partners across the myeloma community to successfully push for panobinostat to be approved. Hundreds of people have benefitted in the years since.
Our ‘Life in Limbo’ research gives an unprecedented insight into the difference carers make to myeloma patients – and the pressures they face.
Hot on the heels of our carer research, we produce new support and information for carers – based on what carers tell us they need most.
Our new Patient Information Panel brings together patients, carers, family and friends. They help produce our information and point out topics we need to cover.
We launch the Patient and Carer Research Panel so more people can help shape life-changing research. Members have since reviewed over 25 research projects.
Our Clinical Service Excellence Programme (CSEP) launches. It recognises hospitals leading the way in myeloma care and helps to raise standards of care nationwide.
We create the Myeloma Palliative Care Outcome Scale, or MyPOS, to measure patients’ quality of life. It lets doctors assess the impact of myeloma and give patients the right support.
We launch ‘The small things that make all the difference’. It’s packed with tips, stories and reflections by and for people affected by myeloma.
We work in all kinds of ways to raise awareness of myeloma, including publishing a book – Kelsey and the Yellow Kite – to help children understand.
Working with partners, we support MUK five – a trial that shows combining carfilzomib, cyclophosphamide and dexamethasone can help stop myeloma coming back after treatment.
Fifteen years after the first event in Edinburgh we hold our 100th Infoday. Giving people the chance to learn more about myeloma from peers and medical professionals.
Just three years after we set up our Translational Research Programme, our team of scientists finds genetic variations linked to a higher risk of myeloma.
Our total income from legacies reaches £1 million. Gifts in Wills allow us to invest in groundbreaking research, bringing hope to patients and families.
When GPs recognise myeloma, it can transform patients’ futures. So we launch the TAKE2 campaign to build awareness of signs, symptoms and how to respond.
Keeping track of symptoms and side effects is important. We launch our downloadable patient diary, where patients can record everything from test results to their thoughts and feelings.
Myeloma drug lenalidomide (Revlimid ®) is rejected for use in England and Wales. So for the second time in two years, we fight back – and win.
We launch the Clinical Trial Network, a groundbreaking collaboration between patients, doctors, researchers, drug companies and the NHS to help patients get new treatments sooner.
We provide funding and support that leads to the first guidelines on recognising and treating MGUS and smouldering myeloma. Both can be connected to myeloma.
Thalidomide can be an important myeloma treatment. We help its manufacturer clarify how it will manage the drug’s risks – and thalidomide is approved across Europe.
Chemotherapy and anti-myeloma drugs are used for AL amyloidosis. But are they effective? Our groundbreaking study reveals that better and tailored treatments are needed.
We set up the UK’s first Translational Research Programme focused on myeloma. It soon gets big results investigating how genes affect myeloma.
The first myeloma drug, bortezomib (Velcade®), is initially rejected for use on the NHS. But, together with 30,000 Myeloma UK supporters, we get the decision overturned.
At our 10-year anniversary dinner, Myeloma UK supporters donate an unbelievable £650,000 to drive our work forward. Your generosity and commitment amaze us every day.
We fund the first guidelines on diagnosing, managing, and treating AL amyloidosis. It’s a landmark moment – setting the expected standard for patients and professionals.
Our total income since forming passes £1 million. We said it then, and we’ll never stop saying it – the myeloma community is incredible.
Our Ask the Nurse email service launched, meaning patients always have someone to turn to for expert advice. Today we answer over 1000 emails every year.
Practical challenges. Emotional challenges. Medical information. Our groundbreaking guide to living well covered them all – answering myeloma patients’ and carers’ biggest concerns.
It is our fifth year of providing emotional support and practical advice on the Myeloma Infoline. Our team of specialists have now helped tens of thousands of people.
In the early 2000s, a lack of evidence-based guidelines meant myeloma patients’ experiences of diagnosis and treatment varied hugely. So we get to work.
Patients and their families join us for the first AL amyloidosis Infoday. It’s now an annual event, with around 100 people joining us every year.
Nurses play a vital role in myeloma patients’ lives. But when we launch there were very few specialist myeloma nurses – and no myeloma education programmes for nurses.
We run the first Myeloma Awareness Week, helping thousands more people understand the signs and symptoms of myeloma. It’s been an annual event ever since.
With big gaps in myeloma knowledge and far too little research, we launched our first research grants. We’ve since invested almost £19m in new studies.
We start publishing resources on AL amyloidosis, a rare condition related to myeloma. We’ve 23 produced publications about it since then, plus our annual magazine.
When we launched, getting the latest, evidence-based information about myeloma in the UK was anything but easy. So we set about changing that.
We begin life as the UK branch of the International Myeloma Foundation. Our goal? Simple. We’re here to improve myeloma patients’ lives.
It’s only with the help of generous supporters that we can provide the best possible support and fund research that improves diagnoses, treatment and care.
Everything we do is funded by voluntary contributions, fundraising and gifts left in wills
The Association of Medical Research Charities (AMRC) is dedicated to helping medical research charities save and improve lives through research and innovation.
The Helplines Standard is the nationally recognised quality standard which defines and certifies best practice in helpline work.
The Patient Information Forum’s Trusted Information Creator is Europe’s only assessed quality mark for online and printed health information.
The Scottish Fundraising Adjudication Panel is responsible for fundraising standards in Scotland and handles any fundraising complaints related to Scottish registered charities.